Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Net Income (2016 - 2025)

Abeona Therapeutics has reported Net Income over the past 15 years, most recently at -$20.5 million for Q4 2025.

  • Quarterly results put Net Income at -$20.5 million for Q4 2025, down 120.17% from a year ago — trailing twelve months through Dec 2025 was $78.0 million (up 264.42% YoY), and the annual figure for FY2025 was $71.2 million, up 211.69%.
  • Net Income for Q4 2025 was -$20.5 million at Abeona Therapeutics, down from -$5.2 million in the prior quarter.
  • Over the last five years, Net Income for ABEO hit a ceiling of $124.3 million in Q2 2025 and a floor of -$46.7 million in Q4 2021.
  • Median Net Income over the past 5 years was -$13.2 million (2022), compared with a mean of -$8.1 million.
  • Biggest five-year swings in Net Income: plummeted 194.85% in 2021 and later soared 1578.98% in 2025.
  • Abeona Therapeutics' Net Income stood at -$46.7 million in 2021, then skyrocketed by 71.9% to -$13.1 million in 2022, then fell by 1.56% to -$13.3 million in 2023, then surged by 30.22% to -$9.3 million in 2024, then tumbled by 120.17% to -$20.5 million in 2025.
  • The last three reported values for Net Income were -$20.5 million (Q4 2025), -$5.2 million (Q3 2025), and $124.3 million (Q2 2025) per Business Quant data.